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Introduction 
Atrial  fibrillation  (AF)  is  one  of  the  most  common 
types  of  sustained  dysrhythmia;  however,  there  are 
some  disagreements  about  AF  treatment.  The 
prevalence of AF in adult population is 4% and rises 
with age, from 0.5% in 25 to 35-year old patients to 5% 
in 69-year old  ones.
1-4 patients  with rapid  ventricular 
response AF frequently require hospitalization. Long-
term  high  ventricular  rate  can  lead  to  tachycardia-
mediated cardiomyopathy.
2,5 The goals of AF treatment 
include the control of ventricular rate, the establishment 
of  sinus  rhythm,  the  prevention  of  thromboembolic 
events  and  the  elimination  of  predisposing  factors.
5-7 
Rates  of  complications  and  death  among  patients 
treated with rate control and rhythm control protocols 
demonstrated no difference.
6 The optimal level of heart 
rate  in  AF  is  unknown.
5-8  Approximately  60-70%  of 
patients with AF have rapid ventricular response and 
the  symptoms  and  complaints  of  patients  usually 
depend  on  the  ventricular  rate.  In  emergency 
department (ED), the first target is usually the control 
of  ventricular  rate.
6,7,9  The  clinical  guidelines  of  the 
American  Heart  Association  (AHA)  and  European 
Society of Cardiology have classified atrial fibrillation 
into  4  types:
7,10  first  detected  episode,  paroxysmal 
(terminates  spontaneously),  persistent  (electrical  or 
pharmacologic  termination  is  necessary),  and 
permanent AF (resistant to electrical or pharmacologic 
conversion or accepted by physicians).
7,11,12 According 
to the AHA protocol in heart failure patients with atrial 
fibrillation,  IV  beta  blockers  and  nondihydropyridine 
calcium channel blockers like diltiazem are the drugs of 
choice  for  acute  rate  control  in  patients  with  rapid 
response AF. Digoxin and amidarone could be used for 
rate control in congestive heart failure patients, but the 
potential risk of cardioversion to sinus rhythm should 
be  considered  with  amiodarone.
13-15  In  this  study, 
digoxin and verapamil were administered by attending 
physicians  and  we  observed  and  compared  the  heart 
rate control of AF patients who came to the emergency 
department. 
 
Materials and Methods 
This  study  was  approved  by  ethics  committee  of 
Tehran  University  of  Medical  Sciences.  The  study 
involved 60 patients presented with rapid response AF 
who  came  to  the  emergency  department  of  Imam 
Khomeini hospital.  
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A rapid ventricular rate was defined as one with more 
than 100 ventricular beats per minute (bpm). Patients 
with systolic blood pressure less than 90 mm Hg, acute 
symptoms or signs of congestive heart failure or acute 
coronary  syndrome,  ventricular  rates  more  than  200 
bpm, coexisting unstable medical conditions (e.g. fever, 
sepsis,  acute  renal  failure,  acute  hepatic  failure, 
thyrotoxicosis, or ARDS), pre-excitation syndrome and 
histories of allergy to verapamil or digoxin and those 
without  the  consent  form  and  taking  any  anti-
dysrhythmic  medications  within  1  week  before 
presentation  were  excluded  from  the  study.  Atrial 
fibrillation  within  the  preceding  72  hours  was 
considered as a new onset AF. 
The study was a descriptive one in which the patients 
were observed in two treatment groups. The selection 
of treatment protocol was done by attending physicians 
(cardiologists) according to patients clinical conditions. 
One group (30 patients) was treated with intravenous 
(IV) verapamil with doses of 2.5 to 15 mg and the other 
group (30 patients) received 0.5 to 1 mg IV digoxin. 
According to the orders of attending physicians, in the 
first group, an initial dose of 0.5 mg IV digoxin was 
given followed by two doses of 0.25 mg IV digoxin at 
8  hours  intervals.  The  second  and  third  doses  of 
digoxin were withheld if the ventricular rate was less 
than 110 bpm at the scheduled dose time. Furthermore, 
the  second  group  received  an  initial  dose  of  2.5  mg 
verapamil followed by repeated 2.5 mg doses (max. 15 
mg)  to  fulfill  heart  rate  control.  All  patients  were 
continuously  monitored  for  heart  rate  and  cardiac 
rhythm in the emergency department for 12 hours. A 
successful rate control was defined as a ventricular rate 
of less than 110 bpm persisting for 1 hour or converting 
to sinus rhythm. The patients were evaluated before, 1, 
2, 4 and 12 hours after the treatment.  
The loss of rate control after receiving 1 mg of digoxin 
or 15 mg of verapamil was defined as an episode of 
increase  in  ventricular  rate  more  than  110  bpm 
persisting for more than 30 min or as a rebound to atrial 
fibrillation in cases where the AF had been converted 
to sinus rhythm. The parameters examined included the 
number  of  patients  with  successful  rate  control  and 
episodes  of  loss  of  rate  control.  The  serum  digoxin 
levels were not measured routinely, but the study was 
designed  to  do  it  in  patients  who  displayed  the 
symptoms or signs of digoxin toxicity.
16 
 
Statistical Analysis 
The  variables  were  expressed  as  frequency  for 
qualitative  variables  and  mean  ±  SD  for  quantitative 
variables  and  were  analyzed  by  repeated  measure 
ANOVA.  The  categorical  variables  were  shown  in 
percentages and were analyzed by chi-square test. A p-
value  of  0.05  was  considered  significant.  All  the 
statistical analyses were performed using SPSS version 
17. 
 
Results 
Sixty patients with AF and rapid ventricular rates, (30 
patients treated with verapamil and 30 patients treated 
with  digoxin)  were  studied.  The  different  chief 
complaints for each group are demonstrated in Table 1. 
The  mean  age  was  60.83±15.65  years  in  verapamil 
group and 66.63±12.47 years in digoxin group which 
did not have a significant difference (P value: 0.1). The 
ventricular  rates  between  two  groups  before  drug 
administration,  1  hour,  2  hours  and  4  hours  after 
treatment  and  successful  rate  control  were  not 
significantly different (Figure1). 
 
 
Table 1. Comparison of chief complaints between two groups 
Chief complaints 
Group 
Total 
Verapamil  Digoxin 
Dyspnea  6(10.0)  8(13.3)  14(23.3) 
Abdominal pain and chest pain  0(.0)  1(1.7)  1(1.7) 
Palpitation  11(18.3)  5(8.3)  16(26.7) 
Hemiparesis  2(3.3)  2(3.3)  4(6.7) 
Fatigue  4(6.7)  2(3.3)  6(10.0) 
Abdominal pain only  3(5.0)  2(3.3)  5(8.3) 
Symptoms of Deep Vein Thrombosis  0(.0)  1(1.7)  1(1.7) 
Vertigo  0(.0)  2(3.4)  2(3.4) 
Chest pain only  3(5.0)  7(11.7)  10(16.7) 
Hematuria  1(1.7)  0(.0)  1(1.7) 
Total  30(50.0)  30(50.0)  60(100.0) 
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Figure 1. Comparison of successful rate control between two 
groups throughout study 
 
Mean  heart  rate  in  both  groups  showed  that  this 
parameter has been significantly reduced until the 4th 
hour  of  evaluation  (p  =  0.002).  No  significant 
difference  in  heart  rate  control  was  noticed  between 
groups  and  both  drugs  were  almost  equally  effective 
(response  to  therapy  was  achieved  in  20  patients  in 
verapamil  group  and  23  patients  in  digoxin  group). 
None of the two drugs converted the patients` rhythm 
to  sinus.  The  best  response  in  verapamil  group  was 
seen  after  average  dose  of  5.92  mg  (46.7%)  and  in 
patients  treated  with  digoxin  was  observed  after 
average dose of 0.61 mg (36.7%)(Table 2). 
 
 
 
Table 2. Comparison of frequency of successful rate control between two groups according to different doses in each group 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Discussion 
AF treatment  goals  include the  control  of  ventricular 
rate,  establishing  sinus  rhythm  and  preventing 
thromboembolic events.
5-7Approximately 60 - 70% of 
patients with AF have rapid ventricular response. The 
control of ventricular rate is usually the first target of 
treatment  in  emergency  department.  King  et  al
17 
recommended  IV  calcium  channel  blocker  or  beta 
blocker  drugs  for  acute  control  of  rapid  ventricluar 
response AF. In our study, the reduction of heart rate 
after  administration  of  digoxin  and  verapamil  was 
studied.  Intravenous  administration  of  verapamil  can 
easily reduce ventricular rate in AF patients. Verapamil 
causes prolongation of the conduction time through the 
atrioventricular  (AV)  node.  The  best  effect  of 
verapamil on AV nodal conduction time and reducing 
rate  happens  during  the  attack  of  tachycardia  and  its 
effect decreases in normal heart rate.
10 
Digoxin has been one of the most common medications 
in control of ventricular rate in AF patients since more 
than  200  years  ago.
7  Digoxin  is  a  positive  inotropic 
agent and used especially in patients with systolic heart 
failure.
9 
In  our  study,  patients  with  AF  had  similar  chief 
complaints  in  both  groups  treated  with  digoxin  and 
verapamil (p = 0.4).  
Mean heart rate in both groups of patients also showed 
that it has been significantly reduced during the 4 hours 
after the treatment (p = 0.002).  
In one study, the effects of intravenous verapamil on 
acute  control  of  ventricular  rate  in  24  patients  with 
atrial fibrillation or atrial flutter were evaluated. In 71% 
of patients (17 cases), after administration of the first 
bolus  dose  of  verapamil  (0.075  mg/kg)  within  60 
seconds,  the  ventricular  rate  decreased  to  below  100 
bpm. All patients who received verapamil (83%) had 
decreased heart rates below 100.
10 
Group  Different doses 
Frequency of 
successful rate 
control 
Successful rate 
control 
Mean dose 
Verapamil 
2.5mg  2 
(20)66.6% 
1.   
5.92±3.11 
2.   
5 mg  6 
7.5 mg  6 
10 mg  3 
15 mg  3 
Total  20 
Digoxin 
0.25 mg  4 
(23)76.6%  0.61±0.26 
0.5 mg  8 
0.75 mg  8 
1 mg  3 
Total  23  
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Schreck  et  al  compared  digoxin  with  diltiazem  in 
controlling AF and showed that diltiazem achieved  a 
rapid reduction in ventricular rate compared to digoxin, 
the results becoming statistically significant (p=0.0006) 
by  5  minutes,  which  maintained  though  the  study 
period.
18  Heart  rate  reduction  with  digoxin  did  not 
reach statistical significance until the end of study and 
there  was  no  benefit  in  addition  of  digoxin  to 
verapamil.
18Waxman  et  al  showed  that  verapamil 
reduced  heart  rate  significantly(p<0.01)  compared  to 
placebo group in patients with AF.
19 In another study 
Phillips  et  al  showed  that  there  were  no  significant 
differences  in  mean  ventricular  response  between 
verapamil and diltiazem.
20 
Jordanes et al and Falk et al in two studies showed that 
digoxin  can  reduce  heart  rate  significantly  after  30 
minutes and after 2 hours in order in patients with acute 
AF, but the persistent slowing of heart rate was only 
seen in 30% of nonconverted patients.
21,22 
Hemels  ME  et  al  showed  that  verapamil  has  no 
beneficial effect in the treatment of patients with AF 
compared to digoxin and it needs future studies.
23The 
evidence  indicates  that  IV  digoxin  can  control 
ventricular  rhythm  within  1  hour  of  administration. 
Digoxin controls heart rate at rest but fails to control 
heart  rate  at  activity  or  excretion.
24  Many  studies 
showed that verapamil decrease heart rate significantly 
at rest and exertion.
25-28 
In  our  study,  the  best  response  to  treatment  with 
digoxin was seen after 0.6 mg (36.7%) and for patients 
who  were  treated  with  verapamil  most  desirable 
response  to  therapy  was  observed  at  5.9  mg  of 
verapamil (46.7%). 
In  our  evaluation  of  heart  rate  control  regarding  the 
definition  (less  than  110  bpm)  over  the  time  of  the 
beginning up to 4 h after treatment showed that the rate 
of improvement in both groups were similar.  
Mean  heart  rate  of  the  patients  measured  by  a  24-h 
holter  monitoring  for  two  weeks  after  entering  the 
study was 82±12 bpm in digoxin group and 84±13 bpm 
in  the  verapamil  group.  The  side  effects  of  digoxin 
were  toxicity,  heart  block  and  bradycardia  and  of 
verapamil  were  hypotension,  heart  block  and  heart 
failure.
23,29 None of these side effects was seen in our 
study. Our study also showed that mean heart rate was 
99.33  ±14.25  bpm  in  the  digoxin  group  and  101.83 
±16.94  bpm  in  the  verapamil  group  (4  hours). 
However, there was no significant difference between 
two groups in heart rate control in the 2nd and 4th hour 
of observation. Heart rate control is achieved after  2 
hours in both groups which was significant (Figure 1). 
Limitations of study: With respects to the fact that in 
our study patients’ evaluation is conducted only until 
twenty four hours after treatment and patient selection 
was not randomized, other studies with randomization 
and  continuous  evaluation  until  discharging  these 
patients are recommended for the future.  
 
 
Conclusion 
Verapamil has no advantage over digoxin in heart rate 
control in patients with acute onset AF.  
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